The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
BUSINESS
Novo Japan’s Revenue Hits Record Yet Again in 2023 with 8.5% Growth
Novo Nordisk Pharma renewed its record in Japan sales yet again in 2023 as its core diabetes franchise continued to enjoy upbeat performances from GLP-1 agents Ozempic (semaglutide injection) and Rybelsus (oral semaglutide). Novo Japan President Kasper Bødker Mejlvang said…
To read the full story
Related Article
- Novo Nordisk Logs 3.6% Growth in Japan in 2024, Driven by Semaglutide
April 28, 2025
- Novo Japan Sales Renew Record in 2022 as Ozempic, Rybelsus Blossom
April 12, 2023
- Novo Japan’s Sales Hit 100 Billion Yen Mark in 2021, but President Frets Future Investments
April 21, 2022
- Novo Japan Notches 10% Growth in 2020, President Proud of This Feat amid Market Decline
April 13, 2021
- Novo Japan Chief Sees 100 Billion Yen Target Achievable on Ozempic, Rybelsus
June 30, 2020
BUSINESS
- Kyowa Kirin’s New Skipper Sees Further Growth Overseas, Vows to Cherish People
May 1, 2025
- Kyowa Kirin CEO Will Now Focus on Strategic Matters and External Dialogue
May 1, 2025
- Japan Pharma Sales Creep Up to 10.8 Trillion in FY2024: Encise
May 1, 2025
- Paxlovid Filed for Pediatric Label Expansion in Japan: Pfizer
May 1, 2025
- Moderna Taps Asia Chief as Japan Representative Director, Marketing Head as GM
April 28, 2025
Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…